Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.14 Consensus Target Price from Analysts
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year […]
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year […]
